Functional roles of CSPG4/NG2 in chondrosarcoma.
CSPG4/NG2 is a multifunctional transmembrane protein with limited distribution in adult tissues including articular cartilage. The purpose of this study was to investigate the possible roles of CSPG4/NG2 in chondrosarcomas and to establish whether this molecule may have potential for targeted therapy. Stable knock-down of CSPG4/NG2 in the JJ012 chondrosarcoma cell line by shRNA resulted in decreased cell proliferation and migration as well as a decrease in gene expression of the MMP (matrix metalloproteinase) 3 protease and ADAMTS4 (aggrecanase). Chondrosarcoma cells in which CSPG4/NG2 was knocked down were more sensitive to doxorubicin than wild-type cells. The results indicate that CSPG4/NG2 has roles in regulating chondrosarcoma cell function in relation to growth, spread and resistance to chemotherapy and that anti-CSPG4/NG2 therapies may have potential in the treatment of surgically unresectable chondrosarcoma.
Centre for Genomic and Experimental Medicine, MRC IGMM, University of Edinburgh, Edinburgh, UK.
Nuor S M
NS
Jamil
Centre for Genomic and Experimental Medicine, MRC IGMM, University of Edinburgh, Edinburgh, UK.
Asim
A
Azfer
Centre for Genomic and Experimental Medicine, MRC IGMM, University of Edinburgh, Edinburgh, UK.
Harrison
H
Worrell
Centre for Genomic and Experimental Medicine, MRC IGMM, University of Edinburgh, Edinburgh, UK.
Donald M
DM
Salter
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology; D001859:Bone Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D002358:Cartilage, Articular / Q000201:enzymology; D002448:Cell Adhesion / Q000502:physiology; D016923:Cell Death / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000502:physiology; D049109:Cell Proliferation / Q000502:physiology; D011508:Chondroitin Sulfate Proteoglycans / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D002813:Chondrosarcoma / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D000077143:Docetaxel; D004317:Doxorubicin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D055785:Gene Knockdown Techniques / Q000379:methods; D006801:Humans; D008297:Male; D008565:Membrane Proteins / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D010447:Peptide Hydrolases / Q000378:metabolism; D034741:RNA, Small Interfering / Q000235:genetics; D043823:Taxoids / Q000494:pharmacology; D055815:Young Adult; D000099216:Chondroitin Sulfate Proteoglycan 4
D000970:Antineoplastic Agents; D011508:Chondroitin Sulfate Proteoglycans; D000077143:Docetaxel; D004317:Doxorubicin; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D010447:Peptide Hydrolases; D034741:RNA, Small Interfering; D043823:Taxoids; C101390:CSPG4 protein, human; D000099216:Chondroitin Sulfate Proteoglycan 4
CSPG4; NG2; chondrosarcoma; therapy